

**Supplemental Figure 1.** Specificity test for antibodies on *Brassica oleracea* stigma proteins

A: Specificities of anti-SRK<sub>3</sub>-N-ter (mAb85-36-71), anti-SRK<sub>3</sub>C-dom, anti-VPS29, anti-SYP21, anti-SYP61 and anti-THL1 antibodies were tested on western blot against total *S*<sub>3</sub> stigma proteins. Anti-SRK<sub>3</sub> antibodies were additionally tested against extracts from the *S*<sub>15</sub>- and *S*<sub>29</sub>-haplotypes as positive and negative controls.

Anti-SRK<sub>3</sub>-N-ter antibody is raised against SRK<sub>3</sub> and in *S*<sub>3</sub> haplotype recognizes the full-length receptor as well as four different glycosylated forms of its splice variant eSRK<sub>3</sub>: two weak ones at 65.2 and 56.7 kDa and two abundant at 62.8 (\*) and 59.5 kDa (\*\*). In *S*<sub>15</sub> haplotype, the antibody recognizes additionally the *S*-locus Glycoprotein (SLG), an abundant protein related to self-incompatibility with high sequence similarity to SRK. Detection of SLG<sub>15</sub> results in strong signal around 60 kDa.


Anti-SRK<sub>3</sub>C-dom antibody is raised against the very C-terminus of SRK<sub>3</sub> and does not recognize SRK from any other known haplotype. Additional cross-reactivity can be seen on western blot, which is not haplotype specific (\*\*\*) . Immunocytochemical experiments show that the cross-reactive proteins are localized in the cell wall (see Figure 4K-M in the main text)

B-D: Specificity of anti-SRK<sub>3</sub>-N-ter for immunolocalization was tested against 10µm-thick sections from *S*<sub>3</sub>, *S*<sub>15</sub> and *S*<sub>29</sub> stigmas. The inserts show the brightfield images.

B: Immunolabeling on *S*<sub>3</sub>-sections using anti-SRK<sub>3</sub>-N-ter antibody. Bar 50µm

C: Immunolabeling on *S*<sub>15</sub>-sections using anti-SRK<sub>3</sub>-N-ter antibody. The highly abundant SLG<sub>15</sub> protein cross-reacts with the antibody, which results in a strong immunofluorescence signal (used as a positive control). Bar 50µm


D: Immunolabeling on *S*<sub>29</sub>-sections using anti-SRK<sub>3</sub>-N-ter antibody. The antibody does not cross react to any protein in *S*<sub>29</sub>-haplotype (used as a negative control). Bar 50µm



**Supplemental Figure 2.** SRK<sub>3</sub> colocalizes with sorting endosome markers after pollination

A-C: Colocalization between SRK<sub>3</sub> (A) and sorting endosome marker VPS29 (C) 50 minutes after self-pollination. Merged image is presented in (B). Images shown are representative of three independent experiments Bar: 10 $\mu$ m

D-F: Colocalization between SRK<sub>3</sub> (D) and sorting endosome marker VPS29 (F) 50 minutes after cross-pollination. Merged image is presented in (E). Images shown are representative of five independent experiments. Bar: 10 $\mu$ m



**Supplemental Figure 3.** Effect of Cycloheximide (CHX) treatment on self-incompatibility.

CHX-pretreated  $S_3$ -stigmas were pollinated with  $S_{15}$ - (A and C) or  $S_3$ - (B and D) pollen grains (cross- or self-pollination, respectively). CHX treatment breaks the self-incompatibility response.

A:  $S_3$  mock-treated stigma accepts growth of compatible  $S_{15}$ -pollen grains.

B:  $S_3$  mock-treated stigma rejects  $S_3$ -pollen grains. The grains fail to adhere on the papilla cell surface and are washed away during the fixation procedure.

C: CHX-treated  $S_3$  stigma accepts growth of compatible  $S_{15}$ -pollen grains.

D: CHX-treated  $S_3$  stigma accepts growth of otherwise incompatible  $S_3$ -pollen grains.

Bars: 100 $\mu$ m